The Myth of Secondhand Vaping: Analyzing the UK Government’s £500M Ban

The UK government is currently evaluating a sweeping ban on vaping across all indoor workplaces, including hospitality venues. However, a deep analytical review of the government’s own Impact Assessment (IA) reveals a profound lack of clinical evidence to support this £500 million regulatory intervention. By systematically deconstructing the foundational studies cited by the World Health Organization (WHO), the European Union (EU), and the Office for Health Improvement and Disparities (OHID), this report demonstrates that “secondhand vapour” poses no quantifiable harm to bystanders. The data indicates that environmental exposure to e-cigarette aerosol is consistently below occupational safety thresholds, often registering lower particulate matter than everyday activities like cooking or lighting a candle.

The £500 Million Solution in Search of a Problem

Last month, the British government initiated a public consultation regarding the prohibition of vaping in all indoor workplaces—a sweeping mandate that would encompass bars, clubs, pubs, shops, and restaurants. From a public policy perspective, this represents a massive regulatory overreach driven by minimal public demand. There has been no organic groundswell of support for such a ban; even traditional public health advocacy groups have not actively lobbied for its implementation.

The economic reality of this proposal is stark. The government’s official Impact Assessment projects the cost of this policy to exceed £500 million. Crucially, the document fails to assign any monetary value to the anticipated health benefits. The reason for this omission is fundamental: the government is currently unable to establish if there will actually be any measurable health benefits.

In an attempt to construct a rationale for banning vaping across six million indoor spaces, the Impact Assessment leans heavily on the theoretical risk of “secondhand vapour” to bystanders. To justify this, the document aggregates a specific selection of international studies and institutional reports. A rigorous clinical review of these citations, however, reveals a pattern of methodological flaws, exaggerated conclusions, and a deliberate conflation of “detectable” chemicals with “harmful” exposure.

Institutional Posturing: The WHO and the EU

To understand the foundation of the UK’s Impact Assessment, we must first examine the primary institutional sources it relies upon: the World Health Organization and the European Union.

The WHO maintains a notoriously hostile regulatory posture toward vaping. The agency’s credibility on this specific issue has been repeatedly challenged, evidenced by the frequent application of community notes on X (formerly Twitter) correcting the organization for spreading misinformation regarding e-cigarettes.

Within the UK’s IA, the WHO is cited as stating that vape aerosols typically raise the concentration of particulate matter indoors and contain “potentially toxic substances.” Therefore, the WHO concludes, these emissions pose “potential risks” to bystanders.

The analytical red flag here is the strategic use of the word “quantifiable” rather than “harmful.” Modern spectrometry can quantify the tiniest, most microscopic chemical traces. No environment on Earth—indoor or outdoor—is entirely free of airborne particles that could theoretically be harmful if consumed in massive, unrealistic quantities. Furthermore, the WHO citation is not a peer-reviewed meta-analysis; it is simply a webpage formatted as a Frequently Asked Question (FAQ) concerning ENDS (Electronic Nicotine Delivery Systems). The WHO provides zero supporting clinical evidence for its claims on this page, carefully restricting its language to “potential risks.”

The second foundational pillar of the IA is an EU council recommendation from 2024 advocating for “smoke- and aerosol-free environments.” Heavily influenced by the WHO, this document cites five peer-reviewed studies to argue that e-cigarettes expose bystanders to “quantifiable levels of particulate matter and key toxicants.”

Once again, the presence of a chemical does not equal pathology. Let us deconstruct the five specific studies the EU relies upon:

1. The Baseline Reality: Fernández et al. (2015) measured PM2.5 (particulate matter 2.5 micrometres or smaller). They found the median concentration in an e-cigarette user’s home was 9.88 μg/m3. In completely smoke-free, non-vaping homes, the level was 9.53 μg/m3. The authors themselves admitted these figures are functionally similar. To understand how negligible this is, the PM2.5 concentration in a traditional smoker’s home was recorded at a staggering 572.52 μg/m3.
2. Unrealistic Exposure Models: Li et al. (2020) conducted a literature review that openly predicted secondhand vaping would become a public health problem. To support this predetermined conclusion, they highlighted unusually high PM2.5 readings generated in highly artificial environments, including a densely packed vape conference, an exposure chamber utilizing a smoking machine, and a laboratory setting where the measuring device was placed just 50cm from the vaper’s mouth. These scenarios do not replicate real-world workplace exposure.
3. Contradictory Conclusions: Hess et al. (2016), an Australian literature review, presents a fascinating contradiction between its data and its conclusion. The study’s actual findings reported:
   • “No significant risk of harm to human health from exposure to the levels of tested chemicals.”
   • “No difference was found in lung function for the nonsmokers passively exposed to EC vapour.”
   • Short-term exposure “did not seem to lead to the inflammatory response” seen with conventional cigarettes.
     Despite this overwhelming lack of clinical pathology, the authors inexplicably concluded that there is a “potential for health impacts.”
4. Animal Models vs. Human Reality: Lerner et al. (2015) subjected mice to “acute exposure” of aerosols, finding inflammatory responses. Human trials have consistently failed to replicate these results, primarily because humans in everyday environments are not subjected to the unrealistically massive, concentrated doses forced upon laboratory mice.
5. Negligible Aerosol Production: Borgini et al. (2021) evaluated two vapers in a room. The aerosol production was so minimal that the researchers essentially abandoned measuring PM2.5. As noted by industry analyst Roberto Sussman, the study primarily served to show that different device brands produce slightly different, but ultimately negligible, vapor volumes.

(Note: The EU document also inexplicably cites a study by Glantz et al. (2024) which does not even investigate secondhand emissions. It is worth noting that Stanton Glantz is a highly controversial figure with a history of retracted papers regarding vaping).

• Read more: Study Reveals Vaping Around Children Exposes Them to Significantly Less Nicotine Than Secondhand Smoking

Deconstructing the UK Impact Assessment Citations

Moving beyond the EU, the UK Government’s Impact Assessment directly cites three specific studies to build its case against indoor vaping. A clinical audit of these papers reveals severe methodological limitations.

Amalia et al. (2023) investigated the homes of 29 vapers. In eight of these homes, researchers could not detect any ambient nicotine whatsoever. In the remaining homes, the average level was 0.01 μg/m3 (one-hundredth of a microgram per cubic metre). In standard environmental tobacco smoke research, this microscopic level is officially considered below the limit of quantification. Furthermore, the study found absolutely no statistically significant difference in particulate matter between vapers’ homes and non-vapers’ homes. While bystanders did show trace amounts of cotinine (a nicotine biomarker), the levels were biologically insignificant. (Roberto Sussman provides a deeper technical breakdown of this study here).

Tattan-Birch et al. (2024) evaluated children living with vapers. They found that these children absorb more cotinine than unexposed children. However, context is everything in toxicology. The blood cotinine levels in these “secondhand vapers” averaged 0.08 μg/L. To understand how homeopathically small this is:

• Children exposed to secondhand smoke averaged 0.49 μg/L.
• An active, average adult vaper registers around 250 μg/L.
  The exposure level for bystanders is more than 3,000 times lower than that of an active user. Furthermore, cotinine itself is a harmless biomarker, not a carcinogen.

Islam et al. (2022) represents a masterclass in flawed epidemiological methodology. This Californian cross-sectional study claimed that secondhand vaping caused a 40% increase in bronchitis and a 53% increase in shortness of breath. However, the dataset was hopelessly compromised by confounding variables.

Of the 223 young adults who reported exposure to secondhand vapour:

• Only 6.9% were exclusively exposed to secondhand vapour (meaning they didn’t smoke, vape, or inhale cannabis themselves).
• 48.4% were active smokers/vapers who were also exposed to secondhand smoke.
• 33.2% didn’t smoke themselves but were exposed to actual secondhand combustible smoke.

Attempting to isolate the respiratory effects of secondhand vapour from a cohort heavily exposed to combustible tobacco and cannabis is statistically impossible. The effect size claimed by the researchers was so implausibly high that it suggested passive vaping was more dangerous than active vaping. Unsurprisingly, independent experts heavily criticized this study upon publication.

The OHID Biomarker Evidence: A Failure to Prove Harm

The final pillar of the government’s argument rests on an extensive report published in 2022 by the Office for Health Improvement and Disparities (OHID). This report cites six studies focusing on human biomarkers.

1. Trace Nitrosamines: Martínez-Sánchez et al. (2019) tested the urine of non-vapers living with vapers for a week. Two participants had zero detectable levels of tobacco-specific nitrosamines (NNAL). The other four averaged 0.47 pg/mg (picograms per millilitre). A picogram is one-trillionth of a gram. The authors conceded this is “very low,” noting that active smokers average around 300 pg/mL—a concentration 638 times higher.
2. The Extreme Convention Scenario: Johnson et al. (2019) sent participants into a densely populated e-cigarette convention for six hours. Despite this extreme “cloud-chasing” environment, tobacco-specific nitrosamines remained “below the limit of detection in all samples.” While acrolein was detected, the authors admitted that acrolein is highly prevalent in normal environments, making it impossible to attribute the levels solely to vaping. Cotinine levels peaked at 2.31 μg/g, a level not unusual among non-smokers who are completely unexposed to tobacco.
3. The Wristband Conflict: Two studies by Quintana et al. (2019) and (2021) utilized silicone wristbands to measure environmental nicotine. The data showed that children living with smokers had ten times the exposure of those living with vapers. However, the primary takeaway from these papers seemed to be the efficacy of the wristbands themselves. It is highly relevant that one of the lead authors, Georg Matt—known for inventing the controversial concept of “thirdhand smoke”—declared a financial interest in the company manufacturing these testing bands.
4. Baseline Noise: Melstrom et al. (2018) exposed non-users to two hours of vaping. Blood cotinine readings moved from 0.299 ng/ml to 0.326 ng/ml. This microscopic increase was actually smaller than the natural baseline variation among the participants before the experiment even began. Yet, the authors (including a future head of the FDA’s tobacco division) claimed this “could have important implications for public health policy.” This perfectly illustrates how researchers in this field routinely sideline their own benign data to justify aggressive regulatory posturing.

The Chemical Reality: Liquid Droplets vs. Combustible Particulates

Perhaps the most egregious scientific error in the push for indoor vaping bans is the deliberate conflation of vape aerosol with combustible smoke.

Amalia et al. (2021) measured PM2.5 in a room with a vaper. The highest median reading was 21 μg/m3. The authors were forced to admit that this peak concentration did not even exceed the World Health Organization’s standard for outdoor air quality (25 μg/m3). To put this in perspective, you are exposed to higher PM2.5 levels by lighting a candle or cooking dinner.

More importantly, PM2.5 is a measurement of size, not toxicity. As Roberto Sussman clearly articulates, the particulates exhaled by a vaper are “highly volatile liquid droplets almost entirely composed of glycerol, propylene glycol, nicotine and water.” These droplets evaporate in seconds. Conversely, PM2.5 from atmospheric pollution or tobacco smoke consists of “mostly generated by combustion sources: primary and secondary organic carbon, a wide variety of sulphates and nitrates, hydrocarbons, metals and crustal material.”

Treating exhaled water and glycerol droplets as if they carry the same toxicological weight as combusted carbon and heavy metals is scientific malpractice.

The Counter-Consensus: Occupational Data and True Public Health

While the UK Impact Assessment cherry-picks studies that emphasize “potential” risks, it ignores a wealth of definitive occupational health data.

When the U.S. Department of Health and Human Services (NIOSH) conducted rigorous air sampling inside an active, poorly ventilated vape shop—representing the most extreme exposure scenario possible—they found that all chemicals in the air were strictly below the occupational exposure limit. Similar independent studies have corroborated this, finding undetectable nicotine concentrations in ambient vape shop air.

A comprehensive systematic review published in BMC Public Health concluded there is “no evidence that vaping produces inhalable exposures to contaminants of the aerosol that would warrant health concerns by the standards that are used to ensure safety of workplaces.” They noted that bystander exposure is “orders of magnitude less, and thus pose no apparent concern.”

This aligns perfectly with the historical stance of Public Health England, which stated explicitly in 2016: “There is no evidence of harm to bystanders from exposure to e-cigarette vapour and the risks to their health are likely to be extremely low.” PHE advised against blanket workplace bans because they falsely equate vaping with smoking, thereby discouraging smokers from making a life-saving transition.

Strategic Outlook: Policy Driven by Panic, Not Data

As Prof Peter Hajek, Director of the Tobacco Dependence Research Unit at Queen Mary University of London, definitively states:

“Health risks to bystanders are most likely reduced by a much bigger margin, and most likely altogether. This is because e-cigarettes release no chemicals into the environment themselves, only what users exhale, and such exhalation has so far not been shown to generate any toxicants at levels that could conceivably affect the health of bystanders.”

There is a concerted, well-funded effort by anti-harm-reduction academics to manufacture evidence against “secondhand vapour.” Despite utilizing highly sensitive equipment, closed exposure chambers, and biased methodologies, they have consistently come up empty-handed. The chemical levels measured in bystanders exposed to everyday vaping are microscopically lower than tobacco smoke, lower than standard cooking emissions, and consistently below established safe thresholds for both indoor and outdoor air quality.

The UK government’s £500 million proposal to ban indoor vaping is a regulatory overreaction built on a foundation of scientific sand. It is a policy that ignores clinical reality in favor of institutional panic.

• Read more: Is Secondhand Vapor Harmful? Debunking the Concerns
• Reference: Secondhand vaping: the (lack of) evidence